aTyr Pharma, Inc.

What they do

aTyr builds therapies from a proprietary library of domains derived from all 20 tRNA synthetases, aimed at fibrosis and inflammation. Its lead candidate, efzofitimod, selectively modulates activated myeloid cells through neuropilin-2 (NRP2). Development is focused on ILD, principally pulmonary sarcoidosis and systemic sclerosis-associated ILD (SSc-ILD).

Revenue drivers

• Collaboration and license revenue — Annual revenue was $190,000 in 2025 and $235,000 in 2024, versus $10.4M in 2022, so no product revenue exists today. The only 2025 quarterly revenue recorded was $190,000 in the quarter ended 2025-09-30.
• Efzofitimod (lead candidate) — Pre-revenue. In development for pulmonary sarcoidosis and SSc-ILD; the Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint. No product sales are reported.
• Japan partnership with Kyorin — Kyorin Pharmaceutical Co., Ltd. is the company's partner in Japan, where PMDA granted efzofitimod orphan drug designation for sarcoidosis. No revenue amount from this arrangement is given in the excerpts.

Recent performance

For full-year 2025, revenue was $190,000 and net loss was $74.1M, or $0.80 diluted EPS, with operating cash outflow of $62.0M. Net losses have widened annually from $50.4M in 2023 to $64.0M in 2024 to $74.1M in 2025, while revenue fell to near zero. At 2026-06-30, total assets were $69.8M, shareholder equity $48.8M and cash and equivalents $16.2M. The 2026-08-07 release reported ending the second quarter of 2026 with $58.9M in cash, cash equivalents, restricted cash and investments.

Strategy

The company is prioritizing efzofitimod in ILD, including pulmonary sarcoidosis and SSc-ILD, and restructuring to conserve capital. On 2026-08-07 it announced a workforce reduction of approximately 60%, with expected annualized operating expense savings of approximately $13M beginning in the fourth quarter of 2026. It submitted a protocol to the FDA in June 2026 for a planned Phase 3 study in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease and awaited FDA comments by end-August 2026. It has completed enrollment in the Phase 2 EFZO-CONNECT study in SSc-ILD, with topline results expected in the first quarter of 2027. CFO Jill Broadfoot and General Counsel Nancy Denyes both step down as of September 30, 2026; Brandon Yaras becomes CFO on October 1, 2026.

Risks

• No validated FDA endpoint in pulmonary sarcoidosis — The excerpts state there is no established FDA regulatory pathway for approval in pulmonary sarcoidosis and no FDA-endorsed primary endpoint, so EFZO-FIT may not support approval.
• Phase 3 EFZO-FIT missed its primary endpoint — The study did not meet its primary endpoint of change in mean daily oral corticosteroid dose at week 48 (2.79 mg for 5.0 mg/kg vs 3.52 mg for placebo, p=0.3313), and subsequent analyses are reported only as nominal findings.
• Going-concern and funding risk — Revenue was $190,000 in 2025 against a $74.1M net loss and $62.0M operating cash outflow, and the company has no approved products, so continued funding depends on external capital or partnerships.
• Restructuring and listing events — An approximately 60% workforce reduction, departure of the CFO and General Counsel, and 8-K events on 2025-12-05 and 2026-06-08 described as delisting notice or listing-rule failure indicate organizational and listing strain.

Outlook

Management expects FDA feedback by end-August 2026 on the submitted protocol for a planned Phase 3 study in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. That trial is described as a 54-week, randomized, double-blind, placebo-controlled study of 5.0 mg/kg efzofitimod or placebo dosed intravenously every 3 weeks for 17 doses, enrolling up to approximately 372 patients. Topline results from the Phase 2 EFZO-CONNECT study in SSc-ILD are expected in the first quarter of 2027. The company states its cash runway extends into late 2028 based on current operations, and it expects the restructuring to reduce annualized operating expenses by approximately $13M starting in the fourth quarter of 2026.